Most common, burdensome, and worrisome symptoms experienced by people living with early Parkinson’s disease in Germany and the United States—Results from a cross-sectional survey - Report - MDSpire

Most common, burdensome, and worrisome symptoms experienced by people living with early Parkinson’s disease in Germany and the United States—Results from a cross-sectional survey

  • By

  • Simon Messner

  • Àngels Costa

  • Todd Carmody

  • Rebekah Park

  • Byron Jones

  • Elisabeth Lucassen

  • Amelia Hursey

  • July 8, 2026

  • 0 min

Share

Clinical Report: Prevalent and Distressing Symptoms in Early Parkinson’s Disease

Overview

This study identifies the most common and burdensome symptoms experienced by individuals with early-stage Parkinson's disease (ePD) in the United States and Germany, with tremor reported by all participants and mobility issues and pain noted as significant symptoms, particularly in those diagnosed for 4-5 years.

Background

Parkinson's disease (PD) is a progressive neurodegenerative disorder affecting millions globally. While much research has focused on late-stage symptoms, this study aims to identify the symptom burden in early-stage PD to improve patient care.

Data Highlights

SymptomReported Frequency
Tremor100%
Mobility IssuesReported as burdensome
PainReported as burdensome
Bradykinesia30% higher in 4-5 year group
Memory Loss30% higher in 4-5 year group
Cognitive Impairment30% higher in 4-5 year group

Key Findings

  • All participants reported experiencing tremor.
  • Mobility issues and pain were frequently reported as burdensome symptoms.
  • Bradykinesia, memory loss, and cognitive impairment were reported more frequently in those diagnosed for 4-5 years.

Clinical Implications

The findings highlight the significant burden of both motor and non-motor symptoms in early-stage PD.

Conclusion

The study emphasizes the importance of evaluating symptom frequency and impact in early-stage PD.

Related Resources & Content

  1. Frontiers in Neurology, 2026 -- Discrepancies in symptom concerns and burden from the perspectives of parkinson's disease patients, caregivers, and physicians
  2. Drugs - Real World Outcomes, 2023 -- Financial Impact of Parkinson’s Disease: A Comprehensive, International Cost-of-Illness Analysis
  3. Frontiers in Psychiatry, 2026 -- Incidence of anxiety disorders following Parkinson's disease: a population-based cohort study
  4. Frontiers in Neurology, 2026 -- Most common, burdensome, and worrisome symptoms experienced by people living with early Parkinson's Disease in Germany and the United States
  5. Brain — Cognitive and neuropsychiatric profiles distinguish atypical parkinsonian syndromes
  6. Dopaminergic Therapy for Motor Symptoms in Early Parkinson Disease
  7. EMA considers new biomarkers, patient populations in proposed Parkinson’s disease guideline update
  8. Frontiers | Parkinson’s disease beyond motor symptoms: a review of the validity and limitations of current classification of non-motor symptoms
  9. Sex differences in the severity of non-motor symptoms in Parkinson’s disease: a systematic review and meta-analysis | npj Parkinson's Disease
  10. Efficacy and safety of intravenous prasinezumab in individuals with early-stage Parkinson's disease on stable symptomatic monotherapy (PADOVA): a phase 2b, multicentre, randomised, double-blind, placebo-controlled study - ScienceDirect
  11. PADOVA Trial Reports Prasinezumab Results in Early Parkinson Disease - ReachMD
  12. Trial of Prasinezumab in Early-Stage Parkinson’s Disease | New England Journal of Medicine
  13. Wearable-sensor based walking and non-walking measures as progression markers in early to mid-stage Parkinson’s disease | npj Parkinson's Disease
  14. Specificity of non-motor symptoms of Parkinson’s disease: A systematic review and meta-analysis - Holly Jackson, Judith Anzures-Cabrera, Rayo Akande, Ronald B. Postuma, Tanya Simuni, Gennaro Pagano, , NMS Meta-Analysis Study Group, NMS Meta-Analysis Study Group, 2026
  15. Nonmotor symptoms in Parkinson’s disease patients in South Asia: A systematic review and meta-analysis - PMC
  16. Plasma neurofilament light chain in early Parkinson's disease predicts motor complications: a prospective cohort study - PubMed
  17. Cerebrospinal fluid dopamine 3-O-sulfate as a novel biomarker for predicting motor complications in Parkinson’s disease: insights from the PPMI cohort | Journal of Translational Medicine | Springer Nature Link
  18. Frontiers | Most common, burdensome, and worrisome symptoms experienced by people living with early Parkinson's Disease in Germany and the United States – results from a cross-sec&onal survey

Original Source(s)

Related Content